Ernexa Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $2.34M
- P/E (TTM)
- –
- Dividend yield
- –
About Ernexa Therapeutics
Pharmaceutical Preparations, SIC 2834
Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company focused on developing cell therapies for cancer, autoimmune diseases, and rare conditions. The company utilizes induced pluripotent stem cell-derived mesenchymal stem cells engineered to deliver therapeutic agents directly to disease sites. Its lead candidate, ERNA-101, is designed to secrete interleukins directly into the tumor microenvironment for conditions like ovarian cancer. In addition, the company develops ERNA-201, an anti-inflammatory cytokine-secreting therapy aimed at autoimmune disorders such as rheumatoid arthritis.
The company operates its principal executive offices in Cambridge, Massachusetts, and conducts research activities through a subsidiary in Texas. It also holds international patent protection covering multiple families across jurisdictions including the United States, Europe, Canada, Japan, and South Korea. Ernexa participates in an international trade acceleration program in Japan to explore development, manufacturing, and clinical partnerships.
Summary of the business section of Ernexa Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Ernexa Therapeutics Inc.
- Headquarters
- Cambridge, MA
- Address
- 1035 Cambridge Street, Suite 18a 02141
- Phone
- (617) 798-6700
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- ERNA
- Other tickers
- ERNAW
- Exchange
- Nasdaq
- Shares outstanding
- 2M, Aug 6, 2026
- Public float
- $17.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, May 4, 2026; 1-for-15 reverse, Jun 12, 2025; 1-for-20 reverse, Oct 17, 2022; 6-for-1, May 17, 2021; 1-for-2 reverse, Mar 26, 2021; 1-for-50 reverse, Aug 4, 2016; 1-for-50 reverse, Jun 17, 2016
- SEC CIK
- 748592
- CUSIP
- 114082407
- ISIN
- US1140824079
- EIN
- 31-1103425
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sanjeev Luther | President and CEO, Director | – |
| Sandra M. Gurrola | Sr. VP of Finance | 110 |
| Robert J. Spiegel | Director | – |
| James Arthur Bristol | Director | – |
| William A. Wexler | Director | – |
| David Polinsky | Director | 8,000 |
| Peter Cicala | Director | – |
| Elena Ratner | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr Luther | $888.81K | $401.41K | $385.20K | $0 | – |
| FY2025 Non Peo Neo | $385.20K | $336.85K | $385.20K | $0 | – |
| FY2024 Mr Luther | $3.06M | $784.00K | $396.20K | $0 | – |
| FY2024 Non Peo Neo | $396.20K | $296.21K | $396.20K | $0 | – |
| FY2023 Dr Angel | $824.68K | $591.98K | $334.00K | $0 | – |
| FY2023 Non Peo Neo | $334.00K | $328.32K | $334.00K | $0 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 12, 2026, we had five full-time employees, which includes three research and development positions and two administrative positions.”
Corporate history
Events identified from SEC filings